New Drug Approvals Archive - May 2014
Get news by email or subscribe to our news feeds.
May 2014
| May 5 |
Epanova (omega-3-carboxylic acids) Capsules Date of Approval: May 5, 2014
Company: AstraZeneca
Treatment for: Hypertriglyceridemia
Epanova (omega-3-carboxylic acids) is a fish oil-derived mixture of free fatty acids for the treatment of patients with severe hypertriglyceridemia. Epanova (omega-3-carboxylic acids) FDA Approval History |
| May 8 |
Zontivity (vorapaxar) Tablets Date of Approval: May 8, 2014
Company: Merck
Treatment for: Cardiovascular Risk Reduction
Zontivity (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist for the prevention of cardiovascular events in high risk patients. Zontivity (vorapaxar) FDA Approval History |
| May 20 |
Entyvio (vedolizumab) Injection Date of Approval: May 20, 2014
Company: Takeda Pharmaceutical Company Limited
Treatment for: Crohn's Disease -- Acute, Ulcerative Colitis
Entyvio (vedolizumab) is an integrin receptor antagonist for the treatment of Crohn's disease and ulcerative colitis. Entyvio (vedolizumab) FDA Approval History |
| May 23 |
New Indication Approved: May 23, 2014
Vectibix (panitumumab) FDA Approval History |
| May 23 |
Dalvance (dalbavancin) Injection Date of Approval: May 23, 2014
Company: Allergan, Inc.
Treatment for: Skin and Structure Infection
Dalvance (dalbavancin) is a second generation lipoglycopeptide antibiotic for the treatment of adult patients with complicated skin and skin structure infections, including those caused by
methicillin-resistant Staphylococcus aureus (MRSA). Dalvance (dalbavancin) FDA Approval History |
| May 28 |
Natesto (testosterone) Intranasal Gel - formerly CompleoTRTDate of Approval: May 28, 2014
Company: Trimel Pharmaceuticals Corporation
Treatment for: Hypogonadism -- Male
Natesto (testosterone) is a bioadhesive intranasal gel testosterone product for the treatment of male hypogonadism. Natesto (testosterone) FDA Approval History |
| May 30 |
Omidria (ketorolac and phenylephrine) Injection Date of Approval: May 30, 2014
Company: Omeros Corporation
Treatment for: Intraocular Lens Replacement Procedures
Omidria (ketorolac and phenylephrine) is an anti-inflammatory and mydriatic combination added to irrigation solution during cataract surgery and intraocular lens replacement procedures. Omidria (ketorolac and phenylephrine) FDA Approval History |
| January 21 |
New Dosage Regimen: January 21, 2016
Dalvance (dalbavancin) FDA Approval History |
New Drug Approvals Archive
2016
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2015
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2014
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2013
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2012
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2011
January,
February,
March,
April,
May,
June,
July,
August,
October,
November,
December2010
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2009
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2008
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2007
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2006
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2005
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2004
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December2003
January,
February,
March,
April,
May,
June,
July,
August,
September,
October,
November,
December
